Group 1 - The core viewpoint of the article is that Zhuoyue New Energy is advancing its international development strategy through the establishment of a bioenergy project in Thailand, which is a significant step for the company [1][3]. - The bioenergy project will utilize local resources such as kitchen waste oil and palm acid oil to produce 300,000 tons of biodiesel and 100,000 tons of HVO (hydrotreated vegetable oil) / SAF (sustainable aviation fuel) annually [3]. - The total investment for the project is 700 million yuan, which will be implemented in two phases, with the first phase focusing on the biodiesel production line [3]. Group 2 - The products from the bioenergy project will primarily supply markets in Europe, North America, and Southeast Asia, targeting aviation, maritime, and land transportation sectors [3].

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan, aiming to enhance the operation of provincial government industrial funds [6][34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to reach approximately 10 billion yuan in 2024 and continue to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of bio-based long-chain dicarboxylic acids since 2003, breaking the monopoly of chemical synthesis methods [7]. - Ginkgo Bioworks, established in 2008, has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms to drive growth [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings, particularly in the context of AI and automation [15][16].

双方将依托宁波材料所原创的竹基禾塑新材料技术，围绕高性能材料及制品的产业应用方向，开展深层 次产学研协同合作。 在竹材制品制造中，超过50%的竹材原料最终形成不规则外形的加工余料，这些余料多数仅能被低收率 转化为燃料颗粒、竹炭等产品。 而竹基禾塑材料技术的诞生，致力于从根本上解决这一问题，通过 实 现竹材加工余料的"高值材料化" ，将其转化为高性能材料制品 ，为推动全行业更加合理地进行竹材资 源的综合利用、提升全竹产业链附加值，打造关键技术。 近日， 双枪科技股份有限公司 （以下简称"双枪科技"）发布消息称，已与 中国科学院宁波材料技术与 工程研究所 （以下简称"宁波材料所"）正式签订《竹基禾塑复合材料技术转让（专利实施许可）合 同》。 据项目团队专家介绍， 在性能层面 ，竹基禾塑托盘较之塑料托盘更加 耐摔、抗变形、耐腐蚀性强、低 温性能更优 （-20℃仍保持90%以上韧性） 和 可离火自熄 ； 应用场景可覆盖汽车、工业、建材等多个 领域 ，如用于电动汽车的非结构型装饰零部件、室外装饰件等建材，用于替代传统塑料、木塑和木 材；竹基禾塑托盘可服务于光伏产业太阳能光伏板运输、新能源锂电池产业的运输、大型物流企业、 ...

近日 ， 开云集团旗下奢侈品牌Balenciaga在其2026春季成衣系列中，正式推出了采用创新 生物合成丝 绸 制作的服装—— 2款采用生物工程丝蛋白纱线制成的单品 （一件白色衬衫和一件黑色衬衫裙，现已 在指定门店和线上发售） 。 据悉，本次应用的生物合成丝绸由Balenciaga品牌与 德国生物技术公司AMSilk 合作开发。 声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由仅作新材料相关领域介绍，本文不构成任何投资 建议！转载请注明来源！ 生物，利用细菌发酵工艺，以植物源糖分为原料生产高性能丝蛋白聚合物，最终产品具有纯素、可 100%生物降解且不含微塑料的特性。 2026年3月31日-4月1日， " 第五届中国合成生物学及生物制造大会 " 将 在 杭州 隆重举行，其中设置 【 生物 基化学品与材料专场 】 ，诚邀各位专家及相关从业者参会交流！点击下方小程序卡片，立即免费报名参会！ 会议演讲/路演报名（审核制） 请添加下方微信 该技术利用基因编辑与蛋白质工程， 以蜘蛛丝蛋白的基因序列为模板，对微生物进行改造 。随后，这 些工程化微生物 在生物反应器中发酵，产出特定的丝蛋白，最终纯 ...

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan [6][34]. - Jintou Shengyuan aims to enhance the operation of provincial government industrial funds and support the establishment of a modern industrial system in Zhejiang [34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to be approximately 10 billion yuan in 2024, continuing to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of long-chain dicarboxylic acids through biological methods, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research and product offerings, particularly in the context of AI and automation [15][16].

大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 承办单位 | 享融智云 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 论坛设置 0 2 | | 会场一 | 会场二 | 会场三 | | --- | ...

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan, aiming to enhance the operation of provincial government industrial funds [6][34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%. It is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to reach approximately 10 billion yuan in 2024 and continue to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of bio-based long-chain dicarboxylic acid since 2003, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks, established in 2008, has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing desired biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector, highlighting the need for investment in innovative technologies and platforms to drive growth [19][25]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings, particularly in the context of AI and automation [15][16].

Group 1 - The core viewpoint of the article highlights the collaboration between Zhejiang Sugar Energy Technology Co., Ltd. and Jiangnan University to establish a joint innovation center focused on biobased materials in the food application sector [1][3] - The joint innovation center aims to develop and transform green antibacterial products and functional health foods, centering on food-grade 5-hydroxymethylfurfural (5-HMF) [3] - The center will operate under a "dual-base, co-management" model, ensuring seamless integration of research and industrialization, with Sugar Energy providing funding and high-quality raw materials while Jiangnan University manages technical research and daily operations [3] Group 2 - The construction of Sugar Energy's 10,000-ton 5-HMF production project is set to be completed by December 29, 2025, with production expected to start in June 2026 [4] - The chairman of Sugar Energy stated that this project represents a significant leap towards the industrialization of the company's core technological achievements and aligns with the national "dual carbon" strategy [4] - Founded in 2017, Zhejiang Sugar Energy Technology Co., Ltd. is a national high-tech enterprise focused on the design, development, production, and application promotion of biobased new materials, particularly 5-HMF and its derivatives [4]

生物基材料作为替代传统石油基制品的关键方向，正迎来重要发展机遇。其中， 呋喃生物基材料 PEF 凭借高阻隔性、全生命周期低碳等优势，被视为下一代 聚酯材料的核心代表。 利夫生物 作为国内 FDCA 与 PEF 产业化领军企业，已先后建成百吨级、千吨级产线，其 万吨级生产线正在建设中 。 此外，利夫生物还 开拓了生物基芳香 族材料在食品饮料、纺织服装、3C汽车等领域的应用 ，与众多全球龙头企业建立了战略合作伙伴关系。 3）在包装领域，PEF具备数倍于传统食品接触材料的阻隔性，是理想的敏感性内容物包装材料，目前正在饮料、啤酒、果汁等场景广泛落地。 4）在纺织服装领域，利夫生物所创立的BioFleax™（PEF纤维），具备优异的吸湿速干性能、天然抑菌防螨性能、本征防晒性能，目前正被众多国际一线 品牌用于高性能服装开发。 为此，synbio深波有幸邀请到了 利夫生物CMO罗钊先生于 1月22日晚上20:00 在【synbio深波视频号】进行直播分享 ， 直播 分享主题： 《 高性能呋喃生物 基材料PEF的研发和产业化 》 。 点击下方，立即 预约直播 ！ （*预约后直播开始时微信会自动提醒） 锁定1月22日晚20:0 ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由仅作新材料相关领域介绍，本文不构成任何投资 建议！转载请注明来源！ 近日， 第三代生物可降解塑料研制商 北京中科可蓝新材料科技有限公司 （以下简称"中科可蓝"）宣布 完成 数千万元天使+轮融资 ，本轮融资由江苏省市级国资平台金桥基金、中国新材料领域"独角兽"企 业安徽丰原生物联合投资，老股东麟阁创投超额跟投，所筹资金将用于产品研发迭代、产能规模扩充及 规模化商业落地。 据悉，中科可蓝成立于2024年， 专注于 第三代生物可降解塑料PDA （Polyesters Bio-Degradable in All Nature Environment） 的研发与制造 。 由全球生态塑料领域的著名科学家、俄罗斯工程院外籍院 士、中国科学院理化技术研究所研究员 季君晖博士 发起创立 。核心技术和团队源自中科院理化所工程 和生态塑料国家工程研究中心。 PDA （Polyesters Bio-Degradable in All Nature Environment）是由中科可蓝研发的全球首款可在土 壤、堆肥、淡水、海洋等全自然域环境中完全降解的塑料，降解 ...